LIMN
Liminatus Pharma, Inc. Class A Common Stock
There isn't enough reported data to score LIMN yet.
LIMN Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
LIMN's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
LIMN PE Valuation
LIMN has no meaningful PE right now: it lost money over the past year.
LIMN Forward outlook
There aren't enough analyst estimates for LIMN to show an outlook.
LIMN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | -$137.00 | -$113.97 |
| Q2 2025 | -$137.98 | -$117.44 |
LIMN lost $137.00 per share over the past year, a bigger loss than the year before.
LIMN Quarterly Revenue
LIMN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$970K | +$8M |
| Q1 2026 | -$2M | -$2M |
| Q4 2025 | -$386.8K | -$246.2K |
| Q2 2025 | -$9M | -$8.3M |
| Q1 2025 | $0 | +$903.7K |
| Q4 2024 | -$140.7K | +$486.4K |
| Q3 2024 | -$729.4K | -$190K |
| Q2 2024 | -$687.9K | -$492.7K |
LIMN has burned cash in almost every quarter: −$12M over the past year, against −$2M the year before.
LIMN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +34% | +248K shares |
| 1 year | +584% | +826K shares |
LIMN has 967,966 diluted shares, up 584% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q3 2024 | $537,200 |
| Q2 2024 | $1.3M |
| Q1 2024 | — |
| Q4 2023 | $10.7B |
| Q3 2023 | $10.4M |
| Q2 2023 | $6,577 |
| Q1 2023 | $305,008 |
LIMN Net Leverage
LIMN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LIMN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 35.8 | Neutral |
| Stochastic | 2.8 | Oversold |
LIMN's weekly RSI is 36 (neutral) and its Stochastic is 3 (oversold).
LIMN PE vs Healthcare Sector
LIMN has no meaningful PE right now: it lost money over the past year.
LIMN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.25 | 15% below |
| 20 week MA | $4.39 | 37% below |
| 50 week MA | $14.1 | 80% below |
LIMN is in a downtrend: it's below all three of its weekly moving averages, and 80% below its 50-week average.
LIMN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2025 | $402.0 | $32.4 | -92% |
| 2026 YTD | $32.4 | $2.77 | -91% |
LIMN has finished every year since 2025 lower, and it's down 91% so far in 2026.